The immunotherapy in gastrointestinal stromal tumors
Last Updated: Wednesday, August 28, 2024
Treating gastrointestinal stromal tumors (GISTs) with tyrosine kinase inhibitors (TKIs) significantly reduces the risk of recurrence and prolongs survival. This retrospective analysis of relevant literature looked at the effectiveness of immunotherapy in treating GIST, striving to identify the subset of GIST patients who benefit from immunotherapy.
Advertisement
News & Literature Highlights